Oncologic end points and implication of trial design in the era of immunotherapy for resectable non–small cell lung cancer

[摘要] Featured Editor Note—The field of thoracic surgical oncology has never been more exciting. Within the past year, we are replacing lobectomy with sublobar resection for many patients with non–small cell lung cancer, we are offering neoadjuvant chemoimmunotherapy as standard practice for early-stage disease, and we are treating select patients with resectable non–small cell lung cancer in the adjuvant setting with targeted molecular therapy or immune checkpoint blockade. The backbone of each of these paradigm shifts is practice-changing data from high-impact randomized clinical trials, and the criteria for which we select patients for these therapies in practice are directly translated from the eligibility criteria for entry into these trials.

[学科分类] 心脏病和心血管学

[关键词] non–small cell lung cancer;surgery;immunotherapy;trial design;multimodality therapy